uBriGene

Executive Summary

uBriGene is a global CDMO and CRO specializing in cell and gene therapies (CGT) and advanced therapy medicinal products (ATMPs). Founded in 2015 and headquartered in Fremont, California, the company provides integrated services from preclinical R&D through GMP manufacturing, analytical testing, and regulatory support to commercialization. uBriGene operates across North America and Asia, with a focus on plasmids, viral vectors (AAV, LV), RNA-LNP platforms, and cell therapies including CAR-T and iPSCs. As the CGT market expands, uBriGene is positioned to capture demand for outsourced manufacturing, leveraging its expertise and global footprint. However, as a private, pre-clinical company with limited publicly available financial data, its growth trajectory depends on securing client contracts and scaling capacity. The company's success hinges on execution in a competitive CDMO landscape, where reliability and regulatory compliance are critical.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnerships or multi-year manufacturing contracts70% success
• Q4 2026Expansion of global manufacturing capacity (e.g., new facility in Asia)60% success
• TBDLaunch of novel platform services (e.g., iPSC or RNA-LNP)65% success